<strong>Introduction:</strong><span style="font-family:Verdana;"> Preeclampsia is one of the major causes of maternal and neonatal</span><span style="font-family:""&...<strong>Introduction:</strong><span style="font-family:Verdana;"> Preeclampsia is one of the major causes of maternal and neonatal</span><span style="font-family:""><span style="font-family:Verdana;"> morbidity and mortality in the world. The complexity of its </span><span style="font-family:Verdana;">etio-pathogenesis</span><span style="font-family:Verdana;"> involves, among other things, hypercoagulability, which alone accounts for about 15% of his deaths. Our objective was to study the parameters of coagulation (prothrombin level, activated cephalin time) in pregnant women with preeclampsia and non-preeclampsia at Laquintinie Hospital in Douala. </span><b><span style="font-family:Verdana;">Methodology:</span></b><span style="font-family:Verdana;"> We carried out an analytical cross-sectional case-control study from November 01</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2018 to May 31</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2019, in the gynecology and obstetrics department of Laquintinie Hospital in Douala. We included preeclampsia and non-preeclampsia pregnant women with a gestational age greater than or equal to 20 weeks amenorrhea. The variables of interest were age, pregnancy, parity, gestational age, marital status </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> body mass index, prothrombin level (PL) </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> activated cephalin time (ACT). Hypercoagulability was defined by the presence of at least one of the following abnormalities: PL</span></span><span style="font-family:""> </span><span style="font-family:Verdana;">> 100%, ACT</span><span style="font-family:""> </span><span style="font-family:Verdana;"><</span><span style="font-family:""> </span><span style="font-family:Verdana;">25</span><span style="font-family:""> </span><span style="font-family:Verdana;">seconds. Statistical tests were considered significant for a p-value </span><span style="font-family:Verdana;"><</span><span style="font-family:Verdana;"> 0.05.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> We recruited 150 pregnant women including 50 preeclampsia matched</span><span style="font-family:Verdana;"> with 100 non-preeclampsia. The majority age group in both groups was 25</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">30 years (32% versus 37%). We found a high PL in 58% of preeclampsia versus 22% of non-preeclampsia patients (p = <0.001), a low PL in 8% of preeclampsia versus 0% in non-preeclampsia patients (p = 0.004). The ACT was prolonged in 12% of the preeclampsia versus 0% in the non-preeclampsia patients (p = <0.001). Pregnant women with preeclampsia were 4.89 times more likely to develop hypercoagulability than pregnant women without preeclampsia (OR 4.89;CI 2.34</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">10.20;p = <0.001). In linear regression, preeclampsia was significantly associated with PL (correlation coefficient 0.07;p = 0.008). We did not find risk factors associated with hypercoagulability in preeclampsia.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:""><span style="font-family:Verdana;"> Our study confirms the existence of hypercoagulability associated with preeclampsia, in particular </span><span style="font-family:Verdana;">in relation to</span><span style="font-family:Verdana;"> an increase in the level of prothrombin.</span></span>展开更多
文摘<strong>Introduction:</strong><span style="font-family:Verdana;"> Preeclampsia is one of the major causes of maternal and neonatal</span><span style="font-family:""><span style="font-family:Verdana;"> morbidity and mortality in the world. The complexity of its </span><span style="font-family:Verdana;">etio-pathogenesis</span><span style="font-family:Verdana;"> involves, among other things, hypercoagulability, which alone accounts for about 15% of his deaths. Our objective was to study the parameters of coagulation (prothrombin level, activated cephalin time) in pregnant women with preeclampsia and non-preeclampsia at Laquintinie Hospital in Douala. </span><b><span style="font-family:Verdana;">Methodology:</span></b><span style="font-family:Verdana;"> We carried out an analytical cross-sectional case-control study from November 01</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2018 to May 31</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2019, in the gynecology and obstetrics department of Laquintinie Hospital in Douala. We included preeclampsia and non-preeclampsia pregnant women with a gestational age greater than or equal to 20 weeks amenorrhea. The variables of interest were age, pregnancy, parity, gestational age, marital status </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> body mass index, prothrombin level (PL) </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> activated cephalin time (ACT). Hypercoagulability was defined by the presence of at least one of the following abnormalities: PL</span></span><span style="font-family:""> </span><span style="font-family:Verdana;">> 100%, ACT</span><span style="font-family:""> </span><span style="font-family:Verdana;"><</span><span style="font-family:""> </span><span style="font-family:Verdana;">25</span><span style="font-family:""> </span><span style="font-family:Verdana;">seconds. Statistical tests were considered significant for a p-value </span><span style="font-family:Verdana;"><</span><span style="font-family:Verdana;"> 0.05.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> We recruited 150 pregnant women including 50 preeclampsia matched</span><span style="font-family:Verdana;"> with 100 non-preeclampsia. The majority age group in both groups was 25</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">30 years (32% versus 37%). We found a high PL in 58% of preeclampsia versus 22% of non-preeclampsia patients (p = <0.001), a low PL in 8% of preeclampsia versus 0% in non-preeclampsia patients (p = 0.004). The ACT was prolonged in 12% of the preeclampsia versus 0% in the non-preeclampsia patients (p = <0.001). Pregnant women with preeclampsia were 4.89 times more likely to develop hypercoagulability than pregnant women without preeclampsia (OR 4.89;CI 2.34</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">10.20;p = <0.001). In linear regression, preeclampsia was significantly associated with PL (correlation coefficient 0.07;p = 0.008). We did not find risk factors associated with hypercoagulability in preeclampsia.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:""><span style="font-family:Verdana;"> Our study confirms the existence of hypercoagulability associated with preeclampsia, in particular </span><span style="font-family:Verdana;">in relation to</span><span style="font-family:Verdana;"> an increase in the level of prothrombin.</span></span>